WASHINGTON | A U.S. Medicines Agency (FDA) advisory committee ruled Friday against a third dose of Pfizer’s Covid vaccine for all people aged 16 and over, a move that should be widely interpreted as a setback for the administration of Joe Biden.
The latter has indeed announced a recall campaign for all Americans who received their second dose eight months previously, on condition that the FDA approves it.
American experts have estimated that a third dose could be justified for a smaller age group, namely for the elderly.
The recommendations of this committee are not binding, but it is very rare that they are not followed by the FDA.
In a vote, the majority of the experts on this committee – researchers, epidemiologists, specialists in infectious diseases – voted against a recall campaign for the general population, with 16 votes against and only 2 votes in favor.
In particular, they mentioned concerns about the risks of myocarditis, an inflammation of the heart muscle, in young adolescents and adult males.
It was not clear immediately after the vote whether the experts would vote again, this time on a different age group.
SEE ALSO …
–
